A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.

Inclusion Criteria: * age older than 18 years old * received VV ECMO because of severe respiratory failure Exclusion Criteria: * anticoagulant contraindications * cerebral infarction or suspected patients * severe hypertension * women in gestational and lactational period * hemophilia * allergic to heparin or Nafamostat * unwilling or unable to complete the study